Carfilzomib and Blindness - a phase IV clinical study of FDA data

Summary:

Blindness is reported as a side effect among people who take Carfilzomib (carfilzomib), especially for people who are male, 50-59 old, also take Pomalidomide, and have Multiple myeloma.

The phase IV clinical study analyzes which people have Blindness when taking Carfilzomib. It is created by eHealthMe based on reports of 13,484 people who have side effects when taking Carfilzomib from the FDA, and is updated regularly.

What is Carfilzomib?

Carfilzomib has active ingredients of carfilzomib. eHealthMe is studying from 13,486 Carfilzomib users. Check the latest studies of Carfilzomib.

What is Blindness?

Blindness is found to be associated with 1,509 drugs and 1,986 conditions by eHealthMe. Check the latest studies of Blindness.

On Jul, 18, 2026

13,484 people reported to have side effects when taking Carfilzomib.
Among them, 15 people (0.11%) have Blindness.

Among these 15 people:

What is the gender of people who have Blindness when taking Carfilzomib? *

female: 26.67 %
male: 73.33 %

What is the age of people who have Blindness when taking Carfilzomib? *

What are other drugs people take besides Carfilzomib? *

What are other side effects people have besides Blindness? *

Respirovirus Test Positive: 11 people, 73.33%
Progressive Multifocal Leukoencephalopathy (rapidly progressive neuromuscular disease caused by opportunistic infection of brain cells): 11 people, 73.33%
Papilloma Viral Infection: 11 people, 73.33%
Metastasis (spreadable cancer to other organ from origin): 11 people, 73.33%
Jc Virus Infection: 11 people, 73.33%
Hypoacusis (loss of hearing): 11 people, 73.33%
Blindness Cortical: 11 people, 73.33%
Anogenital Warts: 11 people, 73.33%
Infection Reactivation: 6 people, 40.00%
Seizures (abnormal excessive or synchronous neuronal activity in the brain): 4 people, 26.67%

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 12 people, 80.00%
Progressive Multifocal Leukoencephalopathy (rapidly progressive neuromuscular disease caused by opportunistic infection of brain cells): 4 people, 26.67%

* Approximation only. Some reports may have incomplete information.

Do you take Carfilzomib and have Blindness?

- Check whether Blindness is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Carfilzomib:

Carfilzomib (13,486 reports)

Blindness treatments and more:

Blindness (45,948 reports)

Browse all side effects of Carfilzomib:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Blindness:

Blindness (1,509 drugs)

Browse all the conditions that are associated with Blindness:

Blindness (1,986 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on carfilzomib (the active ingredients of Carfilzomib) and Carfilzomib (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.